University of Copenhagen.
Slagelse Hospital.
Child Dev. 2021 Jul;92(4):1624-1635. doi: 10.1111/cdev.13541. Epub 2021 Jan 28.
A double-blind randomized controlled trial of n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation or matching placebo during third trimester of pregnancy was conducted within the COPSAC mother-child cohort consisting of 736 women and their children. The objective was to determine if maternal n-3 LCPUFA pregnancy supplementation affects offspring neurodevelopment until 6 years. Neurodevelopment was evaluated in 654 children assessing age of motor milestone achievement, language development, cognitive development, general neurodevelopment, and emotional and behavioral problems. Maternal n-3 LCPUFA supplementation during pregnancy improved early language development and reduced the impact of emotional and behavioral problems. The n-3 LCPUFA supplementation was in boys associated with the earlier achievement of gross motor milestones, improved cognitive development, and a reduced impact of emotional and behavioral problems.
一项在 COPSAC 母婴队列中进行的、针对孕期补充 n-3 长链多不饱和脂肪酸(n-3 LCPUFA)或匹配安慰剂的双盲随机对照试验,共纳入了 736 名妇女及其子女。该试验旨在确定母体孕期补充 n-3 LCPUFA 是否会影响后代的神经发育,直至 6 岁。在 654 名儿童中评估了神经发育,评估内容包括运动里程碑的年龄、语言发育、认知发育、总体神经发育以及情绪和行为问题。孕期补充 n-3 LCPUFA 可改善早期语言发育,并减轻情绪和行为问题的影响。n-3 LCPUFA 补充与男孩大运动里程碑的更早达成、认知发育的改善以及情绪和行为问题的减轻有关。